Xickle® RBC-Plus™ is available now. WHY WAIT. Live a Healthier Life!
Connect With Us


  1. Welcome to the Brand-New Xickle.com

    January 13, 2017 by Andrea


    New Year, new look doesn't just mean stocking your closet, home, and makeup bag with fresh finds. We at xickle.com also took the dawning of 2017 as a cue for a major upgrade. And we did it all with you in mind.

    An experience that's much more aesthetically pleasing? We've got that. A collection of articles that's easier to navigate than ever before? Yep, we've got that, too. Plus, you can now connect with us on Twitter and Facebook just by clicking the icons we've integrated into the site.

    But even more importantly, our redesign calls attention to what matters to you most: How Xickle RBC-Plus will actually help sickle cell warriors like you, your family, and your friends. The new homepage, for example, greets you with important information from our recent clinical study presented last month at the American Society of Hematology's annual conference (and also published the the ASH's journal "Blood"). A study that led Dr. Peter N. Gillette -- director of the adult sickle cell program at Downstate Medical Center in New York -- to conclude that “SCD-101 [the drug equivalent of Xickle RBC-Plus] is a promising new drug for the treatment of sickle cell disease, based on the results from the studies reported here ... Clinical benefits included reduced chronic pain and fatigue, improved sleep and improved ulcer healing." The new homepage also provides a look at testimonials and gives easy access to links where you can learn more about the product, our story, and sickle cell news in general.

    "We want to let people with sickle cell disease know there's hope," explains Dr. Eric Coles, Xickle's CEO.

    So, what are you waiting for? Check out some of our most popular posts below and experience our new design for yourself!

    A New Hope: Introducing the New and Improved Xickle RBC-Plus

    Mortality Rates in Pregnant Women with Sickle Cell Slashed

    Why a Warrior’s Mental Health is Just as Important as Physical Health

    3 Ways to Prevent a Crisis in the Colder Months

    We'd love to hear your thoughts on our new look! Hit us up via the contact form and tell us what you think.

  2. A New Hope: Introducing the New and Improved Xickle RBC-Plus

    December 27, 2016 by Andrea
    Photo: CreateHerStock

    Photo: CreateHerStock

    For almost a year, we've been in the process of conducting Phase I of our clinical trial -- the first step on Xickle's journey toward FDA approval. This first phase -- a dose-escalation study -- involved participants with sickle cell taking oral doses of SCD-101, the drug-equivalent of Xickle RBC-Plus.

    Based on the development of herbal medications like Niprisan, SCD-101 is comprised of a proprietary blend of sorghum, pepper, and clove extracts, and is the newly improved formulation of the original Xickle RBC-Plus. This strengthened composition is set to be released the first of the year (2017), and the clinical evidence we've discovered so far is nothing short of promising.

    Our clinical trial participants have reported reduced chronic pain and fatigue, as well as improved sleep and ulcer healing. And we've observed a direct anti-sickling effect on red blood cells that is twice the anti-sickling activity of the initial supplement. 


    For all the details on our clinical trial and its findings, check out our recent presentation for the American Society of Hematology. Phase II of our trial will begin in 2017.

    Xickle RBC-Plus/SCD-101 can protect the structural integrity of red blood cells and can reduce the occurrence of red blood cell clumping. To take advantage of these benefits, visit our website and place your order.

    Wishing you all much health and happiness in the new year!

Sign Up For Xickle's Newsletter!

Get the latest news, health tips and special offers!

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!